Market Overview

UPDATE: Morgan Stanley Reiterates On Cardinal Health On Dublin Day Takeaways

Share:
Related CAH
Earnings Scheduled For August 2, 2017
Jefferies: Weakening Generic Drug Prices Putting Pressure On 3 Healthcare Stocks

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Cardinal Health (NYSE: CAH), but removed the $76.00 price target.

In the report, Morgan Stanley noted, “Contribution from CVS JV should ramp through FY15 with benefit weighted towards 2H, reaching full run-rate in FY16. Lines between channels of trade will likely continue to blur as scale becomes most critical. Importantly the CVS JV provides manufacturers with access to 3 channels (retail, distributor, and mail). JV structure has been well received by existing customers. Longer term, as the gap between top 3-4 buyers and the rest widens, larger pharmacies likely to rethink existing self-warehousing generic strategy.”

Cardinal Health closed on Tuesday at $66.20.

Latest Ratings for CAH

DateFirmActionFromTo
Sep 2017RBC CapitalInitiates Coverage OnSector Perform
May 2017JefferiesInitiates Coverage OnHold
Apr 2017Tigress FinancialInitiates Coverage OnNeutral

View More Analyst Ratings for CAH
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CAH)

View Comments and Join the Discussion!
Loading...
Loading...